Sang Gyu is the founder and CEO of Novelty Nobility and a senior scientist with 25 years of experience in protein and antibody research. Up to now, he has designed more than 200 antibodies and achieved hands-on knowhow in immunization and affinity maturation, which became the impetus of Novelty Nobility’s pipeline development. Sang Gyu is an incumbent professor of Pharmacy at Ajou University and received a Ph.D. in Pharmacy from Seoul National University. He currently serves as an editorial board member of Scientific Reports.

Jin leads finance and business activities at Novelty Nobility. He is an experienced professional in fundraising, deal making and operations at a biotech company and is skillful at translating science into business, and vice versa. At Novelty Nobility, Jin is mostly interested in building a corporate culture that woos talented and decent people, while he himself spends most of the time in crunching numbers and reviewing contracts. He received an MBA from MIT Sloan School of Management.

Jung Tae is an expert in biologics formulation research and an industry veteran with more than 20 years in research and development of antibody and stem-cell therapeutics. During his 20+ year professional career, he has been responsible for the design, research and development of novel antibody therapeutics and biosimilar products at Hanwha Chemical and additional mid-sized biotech companies. Jung Tae received his Ph.D. in Pharmacy from Sungkyunkwan University.

Sukbong began his career in accounting in the mid 90’s and since then has worked for 25 years in general administration. He has accumulated hands-on general operation experience in many companies from start-ups to mid-sized manufacturing companies and feels rewarded through supporting the company's business successes. Trust and responsibility are his lifetime motto, and he is equipped with fatigueless physical strength and unbreakable mental health. No one has ever beaten him in drinking and golf yet.

Sung Tae spearheads Novelty Nobility’s basic scientific research covering target discovery and validation, modality design, mechanism of action, and in vivo proof of concept. His long-term research goal is to find novel mechanism-based biologics and develop therapeutic strategies for preventing the onset or progression of various human disorders. He believes that active communication and open discussion with colleagues, which stimulate their passion and ignite scientific curiosity, are indispensable for the success of any project. Sung Tae received his Ph.D. in Pharmaceutical Sciences from the University of Pittsburgh School of Pharmacy and conducted postdoctoral research at the Brigham and Women’s Hospital & Harvard Medical School before joining Novelty Nobility. 

Arlo directs business development and operations for Novelty Nobility’s US headquarters in Boston, Massachusetts. A chemist and PhD pharmacologist by training, Arlo has blended his science background with an entrepreneurial spirit to start and build several biotech companies over his 20-year career. His experience has included working with products across the entire development cycle from the R&D bench all the way to NDA submission readiness and commercial sale. Outside the office Arlo enjoys biking, hiking, and exploring New England with his wife and two daughters.